Per2 is a C/EBP target gene implicated in myeloid leukemia

Integrative Cancer Therapies
Sigal Gery, H Phillip Koeffler

Abstract

Circadian rhythms are endogenous biological clocks that govern fundamental physiological and behavioral functions. Consequently, perturbations of these rhythms have been associated with pathogenic conditions, such as depression, diabetes, and cancer. CCAAT/enhancer-binding proteins (C/EBPs) are a family of transcription factors that regulate cell growth and differentiation in various tissues and have also been implicated in many cancer types. Using expression profiling studies, we found that the levels of 2 core components of the circadian network, Per2 and Rev-Erb alpha, are significantly altered by C/EBPs. Further studies showed that levels of Per2 were reduced in lymphoma and acute myeloid leukemia patient samples, as well as in lymphoma cell lines. Overexpression of Per2 in hematopoietic cancer cell lines resulted in growth inhibition, cell cycle arrest, apoptosis and loss of clonogenic ability. These results support the emerging role of circadian genes in tumor suppression.

References

Apr 23, 2002·Nature·Kai-Florian StorchCharles J Weitz
May 23, 2002·Cell·Satchidananda PandaJohn B Hogenesch
Aug 2, 2003·Nature Reviews. Neuroscience·Michael H HastingsElizabeth S Maywood
Aug 23, 2003·Science·Takuya MatsuoHitoshi Okamura
Nov 17, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Teresa G GrandaFrancis Lévi
Jan 30, 2007·Nature Reviews. Immunology·Frank Rosenbauer, Daniel G Tenen
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Brooke H MillerJoseph S Takahashi
Aug 12, 2008·Seminars in Oncology·Claudia SchollStefan Fröhling
Sep 20, 2008·Nature Reviews. Genetics·Joseph S TakahashiErin L McDearmon
Oct 11, 2008·PLoS Computational Biology·Jun YanChunxuan Shao
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steffen KoschmiederDaniel G Tenen
Mar 17, 2009·PloS One·Katarzyna BozekHanspeter Herzel
Jun 9, 2009·European Journal of Haematology·Lewin EiseleJan Dürig

❮ Previous
Next ❯

Citations

Mar 29, 2011·Journal of Comparative Physiology. B, Biochemical, Systemic, and Environmental Physiology·Bradley A Buckley
Feb 27, 2013·Biochemical Pharmacology·George AndersonGianluigi Mazzoccoli
Aug 22, 2012·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Xiaoming YangEsmaiel Jabbari
Nov 21, 2014·Molecular Biology of the Cell·Tetsuya GotohCarla V Finkielstein
Apr 17, 2015·Endocrine-related Cancer·Steven M HillDavid E Blask
Jul 5, 2017·Frontiers in Endocrinology·Kiran Padmanabhan, Marc Billaud
Oct 23, 2020·International Journal of Molecular Sciences·Eric López-Huerta, Ezequiel M Fuentes-Pananá
Oct 14, 2021·Molecular Biology Reports·Huihui JiangChengming Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.